ArticlePloS one2015
Human iPS cell-derived insulin producing cells form vascularized organoids under the kidney capsules of diabetic mice.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Bioengineering Pancreatic Organoids and iPSC-Derived β-Cells for Diabetes: Materials, Devices, and Translational Challenges.Bioengineering (Basel, Switzerland) · 2026Review
- Molecular Therapeutics for Diabetic Kidney Disease: An Update.International journal of molecular sciences · 2024Review
- Evaluation of Pancreatic β-cell Differentiation Efficiency of Human iPSC Lines for Clinical UseCurrent stem cell research & therapy · 2024Article
- Functional precision oncology using patient-derived assays: bridging genotype and phenotype.Nature reviews. Clinical oncology · 2023Review
- In Vivo CaBiomedicines · 2023Article
- Making human pancreatic islet organoids: Progresses on the cell origins, biomaterials and three-dimensional technologies.Theranostics · 2022Review
- Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?Frontiers in immunology · 2022Review
- Genome engineering and disease modelingWorld journal of stem cells · 2021Review
- Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models.Frontiers in cell and developmental biology · 2021Review
- Multi-lineage Human iPSC-Derived Platforms for Disease Modeling and Drug Discovery.Cell stem cell · 2020Review
- Concise Review: The Endothelial Cell Extracellular Matrix Regulates Tissue Homeostasis and Repair.Stem cells translational medicine · 2019Review
- Are Tanycytes the Missing Link Between Type 2 Diabetes and Alzheimer's Disease?Molecular neurobiology · 2019Review
- Applications of stem cells and bioprinting for potential treatment of diabetes.World journal of stem cells · 2019Review
- Article
- Establishment of Insulin-Producing Cells From Human Embryonic Stem Cells Underhypoxic Condition for Cell Based Therapy.Frontiers in cell and developmental biology · 2018Article
- Article
- Demethylation of induced pluripotent stem cells from type 1 diabetic patients enhances differentiation into functional pancreatic β cells.The Journal of biological chemistry · 2017Article
- Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis.United European gastroenterology journal · 2017Review
- RETRACTED: Myogenic differentiation of VCP disease-induced pluripotent stem cells: A novel platform for drug discovery.PloS one · 2017Article
- Humans in a Dish: The Potential of Organoids in Modeling Immunity and Infectious Diseases.Frontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Type 1 diabetes (T1D) is caused by autoimmune disease that leads to the destruction of pancreatic β-cells. Transplantation of cadaveric pancreatic organs or pancreatic islets can restore normal physiology. However, there is a chronic shortage of cadaveric organs, limiting the treatment of the majority of patients on the pancreas transplantation waiting list. Here, we hypothesized that human iPS cells can be directly differentiated into insulin producing cells (IPCs) capable of secreting insulin. Using a series of pancreatic growth factors, we successfully generated iPS cells derived IPCs. Furthermore, to investigate the capability of these cells to secrete insulin in vivo, the differentiated cells were transplanted under the kidney capsules of diabetic immunodeficient mice. Serum glucose levels gradually declined to either normal or near normal levels over 150 days, suggesting that the IPCs were secreting insulin. In addition, using MRI, a 3D organoid appeared as a white patch on the transplanted kidneys but not on the control kidneys. These organoids showed neo-vascularization and stained positive for insulin and glucagon. All together, these data show that a pancreatic organ can be created in vivo providing evidence that iPS cells might be a novel option for the treatment of T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.